Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Fountzilas C, et al. Among authors: kalinski p. Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. Clin Cancer Res. 2021. PMID: 34645646 Free PMC article. Clinical Trial.
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Mahalingam D, Wilkinson GA, Eng KH, Fields P, Raber P, Moseley JL, Cheetham K, Coffey M, Nuovo G, Kalinski P, Zhang B, Arora SP, Fountzilas C. Mahalingam D, et al. Among authors: kalinski p. Clin Cancer Res. 2020 Jan 1;26(1):71-81. doi: 10.1158/1078-0432.CCR-19-2078. Epub 2019 Nov 6. Clin Cancer Res. 2020. PMID: 31694832 Free PMC article. Clinical Trial.
Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.
Oshi M, Kawaguchi T, Yan L, Peng X, Qi Q, Tian W, Schulze A, McDonald KA, Narayanan S, Young J, Liu S, Morris LG, Chan TA, Kalinski P, Matsuyama R, Otsuji E, Endo I, Takabe K. Oshi M, et al. Among authors: kalinski p. Am J Cancer Res. 2021 Jul 15;11(7):3628-3644. eCollection 2021. Am J Cancer Res. 2021. PMID: 34354864 Free PMC article.
Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O'Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S. Sarma M, et al. Among authors: kalinski p. Breast Cancer Res Treat. 2022 Apr;192(2):411-421. doi: 10.1007/s10549-021-06506-y. Epub 2022 Jan 9. Breast Cancer Res Treat. 2022. PMID: 35000093 Free PMC article.
Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity.
Orr B, Mahdi H, Fang Y, Strange M, Uygun I, Rana M, Zhang L, Suarez Mora A, Pusateri A, Elishaev E, Kang C, Tseng G, Gooding W, Edwards RP, Kalinski P, Vlad AM. Orr B, et al. Among authors: kalinski p. Clin Cancer Res. 2022 May 13;28(10):2038-2049. doi: 10.1158/1078-0432.CCR-21-3659. Clin Cancer Res. 2022. PMID: 35046055 Free PMC article.
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.
Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, Zhang Y, Gomez EC, Morreale B, Senchanthisai S, Li J, Turowski SG, Sexton S, Sait SJ, Singh PK, Wang J, Maitra A, Kalinski P, DePinho RA, Wang H, Liao W, Abrams SI, Segal BH, Dey P. Alam A, et al. Among authors: kalinski p. Cancer Cell. 2022 Feb 14;40(2):153-167.e11. doi: 10.1016/j.ccell.2022.01.003. Epub 2022 Feb 3. Cancer Cell. 2022. PMID: 35120601 Free PMC article.
165 results